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Summary
Aerosolized antibiotics are a common treatment option for patients with cystic ﬁbrosis
and chronic airway infection, as high doses can be delivered topically to the site of
the infection while systemic exposure is minimized. Patients also use other aerosolized
therapies (e.g. mucus-active agents, airway-wetting agents, and bronchodilators), adding
signiﬁcantly increase timed and complexity to their daily regimen, and often leading to
lower adherence rates. A number of novel technological strategies are available that may
reduce dose frequency and increase the speed of drug delivery. Psychologically based
therapies may also be used to help modify behavior and thus improve adherence to
treatment. Clinicians need to explore both technological and psychological strategies that
will assist in the successful maintenance of treatment requirements.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Cystic ﬁbrosis (CF) lung disease is characterized by en-
dobronchial infection, excessive inﬂammation, progressive
airway obstruction, bronchiectasis, and eventual respira-
tory failure.1 Although multiple species of opportunistic
microbes can be found in the airways of patients with
CF, Pseudomonas aeruginosa is the most prevalent and
is associated with poor outcomes.2,3 Thus, treatment
guidelines emphasize the use of inhaled antimicrobials for
suppression of chronic P. aeruginosa infection,4,5 as well
as for eradication of early infection.5 Although they have
not been well studied for the treatment of pulmonary
exacerbations, inhaled antibiotics are commonly used to
help manage such exacerbations.6 Because infection is
localized to the endobronchial space in patients with CF,
aerosolized antibiotics are an attractive option, since high
doses are delivered topically to the site of infection while
systemic exposure is minimized.7 Currently, widely inhaled
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antibiotic treatments available as nebulizer solutions
include tobramycin inhalation solution (TIS; TOBI®; Novartis
Pharmaceuticals, East Hanover, NJ, USA; and Bramitob®;
Chiesi Farmaceutici S.p.A., Parma, Italy) and aztreonam
lysine for inhalation solution (AZLI; Cayston®, Gilead
Sciences, Forest City, CA, USA), whereas colistimethate
sodium (Colomycin®; Forest Laboratories UK Ltd, London,
England, UK; and Promixin®; Proﬁle Pharma Limited,
Chichester, West Sussex, UK) is approved for use in only
a few European countries. In addition to aerosolized
antibiotics, patients with CF often use several other inhaled
therapies, including bronchodilators, mucus-active agents,
and airway-wetting agents. The addition of numerous
aerosol treatments to airway clearance maneuvers means
a treatment burden in excess of 2 hours per day for
many individuals with CF.8 As observed with other chronic
illnesses, both the time and the complexity of a medical
regimen are associated with low adherence rates,9 and there
is no reason to think that this is any different with CF.
Studies of patients with CF estimate signiﬁcant rates
of nonadherence from 20% to 70%, with rates varying
according to the scale used, the content, and the rater.10,11
Adherence rates vary for different aspects of therapy,
with the best rates for medication and the poorest for
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diet and physiotherapy.12 Adherence estimates for inhaled
antibiotics range between 31% and 53%.13 Low rates of
adherence to chronic medications are associated with poor
disease control, absenteeism, and increased exacerbations
in patients with asthma.14,15 Data relating adherence to
patient outcomes were lacking in the ﬁeld of CF until very
recently. Using pharmacy reﬁll records to assess adherence,
Eakin and colleagues found that nonadherence to chronic
pulmonary medications predicted the need for intravenous
(IV) antibiotics and was also associated with lower baseline
lung function.13 Using a large database of health care claims,
Briesacher and associates reported poor overall adherence
with TIS, with only 7% of patients who were prescribed
TIS receiving 4 treatment cycles in 1 year.16 This study
demonstrated a 60% decrease in the risk for hospitalization
in those patients who were adherent to their treatment
regimen. Thus, we now have evidence that demonstrates
a relationship between low usage of chronic medications
(including inhaled antibiotics) and increased exacerbations
requiring IV therapy. Improving patient outcomes rests, in
part, on increasing adherence to chronic therapies.
Since a large part of the adherence problem among
the CF population may relate to the signiﬁcant time
burden associated with the use of inhaled therapies
(including reconstituting the drug, preparing the nebulizer,
and cleaning/disinfecting procedures), it seems logical
that strategies for minimizing the time may improve
patient adherence rates. Recent innovations in aerosol
formulations and devices have been associated with
improved delivery efﬁciency, better airway deposition, and
signiﬁcant reductions in time burden.17 We cannot assume
that reduction in administration time alone, however, will
solve the adherence dilemma. Asthma medications take
only a few seconds to administer via a metered-dose
inhaler (MDI) or dry powder inhaler (DPI), yet adherence
rates are low. Therefore, we also need to consider and
incorporate behavioral and psychotherapeutic approaches
into the treatment paradigm, in order to make certain that
persons with CF achieve optimal outcomes. This paper will
review both the technological and the behavioral aspects
of reducing the treatment burden and improving adherence
among patients with CF.
Variables to consider with the use of inhaled
antibiotics
Strategies that can signiﬁcantly reduce treatment burden
include reducing the dosing frequency, increasing the speed
of drug delivery, and simplifying device cleaning regimens.
As with any inhaled agent, the aerosol variables of particle
size and velocity need to be considered, as well as such
patient variables as age, upper and lower airway size,
disease severity, and suitability of the device for the
individual.18
The pharmacokinetics (PK) and pharmacodynamics (PD) of
the various antimicrobial agents must be taken into consid-
eration when dosing regimens are designed. Aminoglycosides
and ﬂuoroquinolones work by concentration-dependent
killing: the ratio of the maximum drug concentration
(Cmax) or area under the curve (AUC) vs the minimum
inhibitory concentration (MIC) of the organism.19 Beta-
lactam antibiotics demonstrate time-dependent killing –
that is, the longer the concentration remains above the
MIC of the organism, the better the effect. Aminoglycoside
activity is inhibited by sputum,19 and bacteria in bioﬁlms are
protected from antibiotic activity.20 The main strategy for
managing these challenges is to use very high topical doses
to account for the huge variability in patient characteristics,
bacterial sensitivity to antibiotics, and PK/PD parameters.
The loading doses in aerosol delivery devices range from
tens to hundreds of milligrams of drug per dose. To improve
delivery, one can consider optimization of formulations, the
delivery devices, or both.
Formulation strategies
One strategy for reducing the time of administration
is to concentrate the drug formulation. TIS (TOBI) was
approved as a 60mg/mL formulation, with each 300mg dose
taking approximately 15 to 20 minutes to nebulize with a
PARI LC® Plus Jet Nebulizer (PARI Respiratory Equipment
Inc., Midlothian, Virginia, USA).21 A more concentrated
formulation (75mg/mL) of TIS (Bramitob) reduces dosing
time to about 12 minutes using the same nebulizer.22
Combining increased concentration (100mg/mL) with a
faster delivery device – an efﬁcient eFlow® Electronic
Nebulizer (PARI GmbH, Starnberg, Germany) – decreases
the delivery time to 4 minutes.23 There is likely an upper
limit for the maximum concentration of inhaled antibiotics,
with the limiting factors being the capacity to nebulize the
concentrated drug, as well as the ability of patients to
tolerate highly concentrated formulations.
Increasing the residence time of the drug in the lung can
reduce the dosing frequency needed for inhaled antibiotics.
Liposomes have been used to slow the release of drugs,
resulting in a time-release effect in the lung. Although this
approach may result in a lower initial Cmax, it increases
the AUC (which is important with ﬂuoroquinolone use).
Unfortunately, formulations of liposomal beta-lactams are
not very stable. Aerosol antibiotics under investigation
using liposomal formulations include amikacin24,25 and
ciproﬂoxacin.26
One of the most convenient forms of inhalation technology
is the DPI, which is used commonly for patients with asthma
and/or chronic obstructive pulmonary disease. DPIs are
small and portable, are associated with rapid drug delivery
times, and require no special cleaning or disinfection
procedures, thus saving patients even more time. Since
several milligrams of antibiotic need to be deposited in
the lungs, however, more efﬁcient technology is required
than simple milled powders delivered by a typical DPI.
Milled powders are often blended with lactose to help
overcome strong interparticle forces, reducing the amount
of active drug that can be delivered per dose. Newer
engineered powders have been developed to reduce the
need for excipients and improve deaggregation of the
powders into small particles upon inhalation. One spray-
drying technique was used to develop a DPI formulation
of colistimethate (Colobreathe®, Forest Laboratories UK
Ltd., London, England, UK)), which is currently under
investigation.27
Another new generation of engineered powder particles
called PulmoSphere® (Nektar Therapeutics, San Carlos, CA,
USA) was developed for systemic or topical airway targets.28
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Low-density, spherical particles are created by spray drying
an emulsion of perﬂuorocarbons, water, and the compound.
The resulting particles are low-density, porous, and have
reduced interparticle cohesion, thus allowing release of
the drug from a punctured capsule with lower ﬂow rates
than with typical dry powder formulations. Pulmonary
deposition is higher with these engineered powders vs.
classic DPIs.29 Tobramycin inhalation powder (TIP; TOBI®
Podhaler®, Novartis Pharmaceuticals, Basel, Switzerland)
was developed using the PulmoSphere technology to reduce
the patient time burden associated with administration of
TIS. Deposition studies in healthy volunteers demonstrated
similar distribution of the drug in the airways with
TIP vs TIS.29 A study of patients with CF showed that
TIP 112mg divided into 4 capsules approximated the
PK characteristics of TIS 300mg aerosolized with the
PARI LC Plus nebulizer.30 Phase 3 studies subsequently
demonstrated the effectiveness of TIP vs. placebo,31 as
well as similar safety and efﬁcacy of TIP compared
with TIS when administered over 3 month-on, month-off
cycles.32 Patients rated TIP as more convenient than TIS,
and administration time averaged 5.6 vs 19.7 minutes,
respectively, with no cleaning rituals required with TIP.32
TIP was recently approved for use in Europe, Canada, and
some South American countries. Inhaled ciproﬂoxacin using
this technology is under investigation.33 A minimum required
lung volume and airﬂow are still required to activate the DPI,
so use is limited to patients 6 years of age.34
Finally, combining more than one antibiotic into a
single formulation may be effective for improved killing
of P. aeruginosa or targeting other pathogens. A recent
phase 2 study of a liquid formulation of fosfomycin
and tobramycin, combined and delivered by an efﬁcient
eFlow nebulizer, showed improved clinical outcomes and
reduced sputum density of P. aeruginosa and Staphylococcus
aureus, including the methicillin-resistant strain.35 It is
even technically feasible to combine drugs with different
functions, such as mucus-active agents and antibiotics, in
dry powder formulations.36 Although that particular strategy
may seem counterintuitive, it raises the interesting question
of whether inhaled therapies for patients with CF can or
should be combined to reduce the treatment burden and
improve adherence.
Aerosol device technology
The high doses of inhaled antibiotics needed to achieve ad-
equate levels in the lungs are beyond the capability of most
asthma drug delivery systems, including MDIs, multidose
DPIs, and soft-mist inhalers. Besides the aforementioned
dry powder technology, wet nebulizers can also deliver high
doses of medication to the respiratory tract.
Traditionally, jet nebulizers have been used for delivery
of high-payload drugs. These devices are fairly ubiquitous,
as other CF agents (dornase alfa, hypertonic saline) utilize
this technology. Patients of any age can use jet nebulizers,
including infants and young children; however, jet nebulizers
are associated with long nebulization times, high residual
doses, and arduous cleaning and disinfection procedures to
reduce cross infection. Currently, jet nebulizers are used to
deliver the two approved liquid formulations of tobramycin
and the investigational liposomal ciproﬂoxacin.
A new generation of aerosol delivery systems has been
developed that use a vibrating, perforated mesh to generate
the droplets. These devices are portable, silent, do not
require compressed air, and can operate with batteries or
alternating current. The device housing can be designed to
minimize residual dose and drug waste. The particle size
of the aerosol that is produced depends on the size of
the mesh holes and on the drug formulation properties.
Importantly, vibrating mesh nebulizers are much faster than
jet nebulizers at nebulizing the same volume.17,18
One drawback to these devices is a tendency for the
tiny holes of the mesh to clog over time. Some solutions
may be too viscous to pass through a mesh system. Also,
with repeated use, the nebulization time can gradually
increase. Periodic replacement of the mesh is required
to maintain optimal operation. Finally, these devices still
require cleaning and disinfection, and the mesh has to be
handled carefully to avoid damage.
The eFlow Electronic Nebulizer contains a vibrating mesh
platform that can be customized for different formulations.
The medication cup is sloped so that the ﬂuid is guided to the
perforated mesh, thus minimizing the residual volume. An
aerosol chamber conserves the drug during exhalation, and
a mouthpiece with a 1-way valve directs exhaled air away
from the nebulizer. The eFlow nebulizer was used early in
the development of AZLI, to reduce each treatment time to
2 to 3 minutes.37 Customized versions of the eFlow device
are also being used for clinical development with inhaled
levoﬂoxacin (Aeroqin™ [MP-376], Mpex Pharmaceuticals,
San Diego, CA, USA; 4 to 6 minutes per treatment),38
liposomal amikacin (12 to 15 minutes per treatment), and
the fosfomycin-tobramycin combination.
In addition to the customized eFlow nebulizer for
formulations in development, an “open” device was
designed to mimic the particle size and efﬁciency of the
PARI LC Plus Jet Nebulizer. The eFlow Rapid has a similar
residual dose and particle size as the LC Plus, and a smaller
aerosol chamber than the custom eFlow devices. Studies of
this device using TIS in patients with CF revealed higher
sputum levels than with the LC Plus,39 but lower deposition
measured by scintigraphy (reduced by 41%).40 Nevertheless,
the eFlow Rapid is used widely in Europe for such CF
medications as TIS, hypertonic saline, and dornase alpha.
A highly efﬁcient version of the eFlow ((PARI Respiratory
Equipment Inc., Midlothian, Virginia, USA)) was introduced
in the United States as an open device for CF agents
and, more speciﬁcally, for such compounded antibiotics as
tobramycin and colistin. This device delivers medication
faster than a jet nebulizer, with 2 to 4 times the predicted
drug delivery to the lung.17 Therefore, extreme caution
must be used when delivering medications off label with
the eFlow Trio, in order to avoid side effects and toxicity.
Newer aerosol delivery systems, called “smart devices,”
can time the release of aerosol to a speciﬁc portion of
inhalation and/or guide the patient to inhale very slowly
to maximize lung deposition. The I-neb Adaptive Aerosol
Delivery (AAD) device (Philips Respironics, Chichester, West
Sussex, UK) contains a vibrating horn with stationary mesh
and incorporates software that monitors patient breathing
patterns.41 This device adapts to changes in breathing
pattern and releases aerosol during the ﬁrst 50% to 80%
of inspiration, thus conserving drug during exhalation.
The I-neb can be operated either in the tidal breathing
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mode (TBM) or in the targeted inhalation mode (TIM),
the latter of which coaches patients to perform slow,
deep inhalations to maximize aerosol deposition. The I-neb
utilizes auditory, visual, and tactile feedback to alert
patients about proper use of the device, and to signal that
their treatment is complete. The beneﬁts of the TIM mode
are that (1) controlled inspiration can reduce the wide
variability between subjects for aerosol deposition42 and
(2) it shortens the duration of treatment. In a recent study,
the I-neb operated in TIM was associated with a shorter
mean treatment time (3.7 minutes) vs. TBM (6.9 minutes)
with inhaled colistin.43 Mean adherence was also maintained
in the TIM group but declined slightly in the TBM group. The
I-neb is approved for use with colistin (Promixin) in the UK
and is often used off label with other CF medications.
The AKITA2® (Activaero GmbH, Gautling, Germany) is
another device that limits inspiratory ﬂow and incorporates
vibrating mesh technology to optimize aerosol delivery to
the lungs. This device uses a SMART CARD that stores a
patient’s lung function and instructs the device when to
pulse the aerosol during inspiration, thus making it possible
to target proximal or distal airways.44 The AKITA supplies
air from a compressor, so that the patient inhales at a
constant, slow rate of 12 to 15 liters per minute, resulting
in decreased variability in deposition. As with the I-neb, the
prolonged inspiratory phase associated with use of the AKITA
also reduces the time of administration for inhaled drugs. By
controlling the breathing pattern with devices such as the
I-neb and the AKITA, aerosol deposition is higher, distribution
in the airways is more uniform, variability is reduced, and
treatment time is shortened.
Monitoring adherence with technology
Innovations in nebulizer technology include not only
improving the aerosol performance of the device, but also
allowing for the recording of treatments by the patient
at home. Electronic monitoring has been shown to be the
most accurate method of monitoring adherence compared
with such other techniques as prescription reﬁll records and
self-reporting.45 The 2009 Cystic Fibrosis Trust guidelines
recommend that inhaler devices offer feedback on correct
use and incorporate the ability to provide adherence data
to clinicians.46 The I-neb (available in the UK) incorporates
Insight System software, which allows electronic monitoring
of the number of times the device was used, the time of
day, and the duration of each use. In a 1-year study of
28 children with CF, this technology demonstrated overall
adherence to inhaled antibiotics of 60% to 70%, but with
considerable variation within and between participants.47
The I-neb Insight System also allows patients to upload
their data from home onto a server, thus providing remote
access of adherence data to their CF team. In this way,
CF caregivers are able to work with patients to optimize
their adherence and outcomes. This type of electronic data
capture permits CF caregivers to interact with patients
in an open partnership to achieve the common goals of
improving drug delivery and reducing treatment burden.
Adherence data can also be recorded with the AKITA SMART
CARD, and technology exists to use wireless communication
to transmit electronic adherence data. Although these
monitoring technologies are not yet available worldwide
and may impose more work on the health care team, the
accurate measurement of adherence would allow the team
to identify weaknesses and use strategies for improvement.
Behavioral strategies for improving adherence
to treatment
Deﬁning adherence
In order to support and encourage patients to maintain
an often complex and time-consuming treatment regimen,
clinicians must ﬁrst understand how to approach the issue.
Although many attempts have been made to deﬁne patient
behavior when following treatment advice, the term most
commonly used is adherence, which is described as an
active, voluntary, and collaborative involvement of the
patient in a mutually acceptable course of behavior to
produce a desired preventive or therapeutic result.48
Acceptance of the disease, its implications, and the
treatment required to maintain a state of health is key
to how an individual copes with treatment requirements.
Coping behaviors serve to prevent, avoid, or control
emotional distress; consequently, in developing optimistic
ways of coping, individuals believe that their own actions
have an impact on their health, possibly leading to improved
treatment adherence.49
Nonadherence can be interpreted as a method of
controlling distress and blurring what is unacceptable,
thereby providing a sanctuary from the realities of the
disease. For a person growing up with CF, treatment
demands become repetitive, often with no immediate
perceived beneﬁt.50 Although most patients make every
effort to live a “normal” life, deteriorating health
often leads them to constantly redeﬁne their version of
normal.51–53
Evaluating nonadherence
Individuals with CF are required to carry out a multitude
of often complex medical skills on a daily basis, which are
both time-consuming and intrusive. Maintaining a treatment
regimen is often an overwhelming responsibility, which
can be made even more difﬁcult when a child refuses to
cooperate or a young adult has more interesting things to
do.8,54 Older children and adults report poor adherence to
treatment regimens, describing them as wasteful of time,
boring, and different from the normal lives of their peers.
These young adults are determined to live as normal a life as
possible and acknowledge that sometimes they are making
an informed decision not to carry out their treatment.55
Many barriers to treatment adherence exist, mostly in the
areas of personal health beliefs, coping styles, inadequate
knowledge of the disease, peer group pressure, and family
life. In addition, adherence has been shown to be inﬂuenced
by gender, age, socioeconomic status, levels of functional
impairment, poor adjustment, and stressful or traumatic
events.56 Other barriers more directly related to the health
care setting include the behavior of, and interaction with,
health care professionals, lack of information, the level
of technically demanding skills, treatment burden, access
to treatment, and length of time since diagnosis.57 These
barriers are understandable and, to a degree, reasonable.
Health care professionals are often confused by the patient
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who chooses not to adhere, however, making an informed
decision not to follow a regimen with full understanding
of the consequences, especially when evidence suggests
that low rates of compliance are a predictor of disease
exacerbation.15 It is this knowing self-destruction that can
be the most frustrating for health care professionals.
In a questionnaire-based survey, adolescents and adults
with CF did not share their physician’s perception of their
disease severity, with consequent treatment adherence
inﬂuenced by those perceptions. If patients thought they
were well, regardless of the actual extent of their illness,
they did not feel the need to follow treatment advice.58 The
impact of disease management on daily life creates both
a practical and emotional interruption that may become
lifelong. It is understandable that treatments are missed
when there is no obvious or perceived beneﬁt associated
with them.
Measuring adherence
As stated earlier, nebulized treatments are often missed
or overlooked because of the preparation and cleaning
time involved, as well as the time needed for the actual
nebulization process, which often includes more than one
medication. Patients see this time as intruding into their
daily lives, providing no immediate beneﬁt, and becoming
an obvious label of the disease.
Measuring adherence is an inexact science with many
methods tried and failed, including patient reports, clinical
assessment, checking dispensed prescriptions, bottle/tablet
counts, blood tests, and urinalysis. Using electronic
monitoring either covertly or overtly to assess adherence
to nebulized therapy is probably the most accepted and
the most valid.47,49,59–62 Given that nebulized therapy
is frequently missed, ﬁnding a reliable measurement is
useful in planning an intervention and improving rates of
adherence.
Strategies for modifying behavior
We ﬁnd ourselves in a difﬁcult position when a patient either
refuses to adopt a treatment suggestion at the outset or is
noncompliant with one or more treatments over time, and
it is often at this stage that intervention is considered. A
number of psychologically based therapies can be attempted
when exploring reasons for nonadherence to treatment.
Patients are individuals, however, and not all therapies
will suit all patients. Thus, the clinical team and, most
importantly, the clinical psychologist will assess each patient
and try the most appropriate approach.
A collaborative approach to care
A collaborative approach to care is a partnership of
equals and should take into account a patient’s life
experiences, personal health beliefs, and values, providing
him or her with a shared responsibility with treatment
planning and decision-making. In practicing a collaborative
approach, clinicians will communicate with patients using
ﬂexibility and negotiation, as well as sharing facts and
recommendations. In CF care, this approach will involve
the patient as well as his or her family, usually the
parents. Another term used in health care that embraces the
collaborative approach is family- or patient-centered care.
Collaborative care planning puts the family and the patient
at the center of the consultation and encourages them to
participate in treatment decision-making as a process.63,64
Motivational interviewing
Motivational interviewing (MI) uses a guiding style to engage
with patients by establishing a conversation with them;
however, it will only work with patients who are convinced
about the need for change. The principles of MI include
clarifying strengths and aspirations; expressing empathy;
developing discrepancies among thoughts, beliefs, and
behaviors; working with resistance to change rather than
against it; evoking motivation for change; and promoting
autonomy of decision-making. MI aims to help patients
consider why and how they might change, with the therapist
prompting, asking questions, summarizing, and clarifying
whether change might be a possibility. Since it is the
personal experience of the patient that is important in this
type of therapeutic relationship, initially, the therapist must
avoid offering his or her own perspective. When the patient
is thought to be ready, however, the therapist can elicit
practical solutions and offer suggestions.65
Cognitive behavioral therapy
Cognitive behavioral therapy (CBT) is a form of psy-
chotherapy that focuses on changing certain thoughts,
feelings, and behaviors, with the belief being that
they are interconnected. Patients are encouraged to
examine their thoughts and beliefs, and to understand
the link to their behavior, moods, and physical reactions.
CBT explores the underlying thoughts behind emotional
problems, with the aim being to generate alternative, more
balanced thoughts. Therapeutic sessions challenge negative,
automatic assumptions with the intention of generating
rational replies and realistic goals by introducing and
building behavior modiﬁcation. Homework is common with
CBT, with patients asked to complete diaries or carry out
tasks that will test assumptions that may be perpetuating
the problem.66,67
Personal construct psychology
Personal construct psychology (PCP) assumes that we need
to interpret reality according to our own models or personal
constructs of how the world works. Problems arise when we
do not change our personal constructs when they become
harmful. PCP aims to help patients change their personal
construct to a more viable option – for example, constructing
an identity other than a person with CF. This means that the
patient is being asked to try things out to see whether they
work. This may not be a conscious or articulate construct,
but may be inferred from behavioral changes. This form of
therapy assumes that patients are experts in their illness;
however, PCP acknowledges that illness perceptions and
treatment cannot be separated from self-identity and self-
esteem. PCP is often described as a way for individuals to
manage their own problems, as patients know more about
themselves than does anyone else. The purpose of PCP is
to challenge negative perceptions and teach people to ask
themselves questions about their own world views.68
Problem-solving therapy
Problem-solving therapy is a psychological intervention that
aims to help individuals assess the negative impact of
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problems, increase their ability to cope, and minimize the
likelihood of similar problems reoccurring. This strategy is
helpful for those who have poor problem-solving skills with
an inability to generate alternative solutions, those who rely
on others to solve their problems for them, and those who
view all problems as unsolvable, and feel distressed and
upset when faced with a problem.69
Conclusion
CF treatment regimens are lifelong, time-consuming, and
differentiating, often with no immediate perceived beneﬁt.
It is no surprise, therefore, that persons with CF are
nonadherent to aspects of their treatment regimen at
different times throughout their lives. This behavior can be
acknowledged as a normal adaptation to the physical and
emotional intrusion of illness, in which avoidance can be a
useful coping mechanism and form of control.70
Treatment with nebulized drugs has been shown to be
one of the therapies with which patients are least likely
to adhere; however, many potential therapies currently
being investigated will be delivered by aerosol. Health care
professionals need to work with patients and their families
to dismantle the barriers to nonadherence and explore
strategies, both behavioral and technical, that will assist
in maintaining the treatment requirements of the future.
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